West Pharmaceutical Services, Inc. WST SPX

Q: What is the current share price of West Pharmaceutical Services, Inc. (WST)?

As of 2026-07-14 21:23 PDT, West Pharmaceutical Services, Inc. (WST) trades at $357.65 on NYSE. Its 52-week range is $209.39 to $365.74.

Q: What is the market capitalisation of WST?

West Pharmaceutical Services, Inc. (WST) has a market capitalisation of $25.27B on NYSE.

Q: What is the P/E ratio of WST?

WST trades at a trailing price-to-earnings (P/E) ratio of 47.69. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 8.55.

Q: Does WST pay a dividend?

West Pharmaceutical Services, Inc. (WST) currently offers a dividend yield of 0.24%.

Q: What is the return on equity (ROE) of WST?

WST has a return on equity (ROE) of 19.13%. Its return on capital employed (ROCE) is 16.28%.

Q: Is WST a good stock to buy?

This page provides a data-driven analysis of West Pharmaceutical Services, Inc. (WST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Instruments & Supplies · United States

https://www.westpharma.com

Company Profile ↓

$357.65

+59.84% 1Y

Mkt Cap$25.27B

P/E47.69

P/B8.55

Div. Yield0.24%

52W High$365.74

52W Low$209.39

Book Value$42.18

EPS (TTM)$7.50

Company Overview

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 19.1%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 16.3%.

Healthy Margins

Maintains a net profit margin of 16.8%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.11.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $3.07B (+6.3% YoY); net profit $493.70M.
Trailing 12 Months Year-on-year growth — revenue +21.0%, earnings +56.1%.
5-Year Trend Long-term compounding — revenue CAGR 2.1%, profit CAGR -5.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	2.12%
1 Year:	21.00%

Compounded Profit Growth

5 Years:	-5.55%
1 Year:	56.10%

Stock Price Performance

1 Year:	+59.84%
6 Months:	+30.03%
3 Months:	+37.68%
1 Month:	+8.27%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 95% of range

$209.39 $365.74

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)63.45 · Neutral

Price Performance

1M+8.27%

3M+37.68%

6M+30.03%

1Y+59.84%

Valuation vs Sector

P/E of 47.69 is above the sector median of 25.41 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -5.5% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

47.69

Industry PE

25.41

Forward P/E

37.42

PEG Ratio

3.52

Book Value

$42.18

Price to Book

8.55

P/S

7.91

EV/EBITDA

29.47

Dividend Yield

0.24%

Growth (CAGR)

Revenue 5Y

2.12%

Profit 5Y

-5.55%

Revenue (YoY)

21.00%

Earnings (YoY)

56.10%

Profitability & Returns

ROCE

16.28%

ROE

19.13%

ROA

11.21%

Profit Margin

16.85%

Op Margin

21.70%

Gross Margin

36.28%

EPS (Latest Qtr)

$1.92

EPS (TTM)

$7.50

Balance Sheet & Liquidity

Debt/Equity

0.11

Quick Ratio

1.81

Current Ratio

2.71

Debt

$321.00M

Total Assets

$4.11B

Current Assets

$1.83B

Working Capital

$1.32B

Ownership

Promoter Holding

0.64%

Chg in Prom Hold

FII / Inst Holding

104.00%

Chg in FII Hold

0.06%

Financial Snapshot

Enterprise Value

$25.27B

Total Revenue (TTM)

$3.22B

EBITDA

$869.90M

Free Cash Flow

$275.66M

Operating Cash Flow

$715.30M

Shares Outstanding

70.65M

Gross Margin

36.28%

Payout Ratio

11.50%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	WST West Pharmaceutical Services, Inc. SPX	357.65	47.69	$25.27B	0.24%	16.28%	19.13%	2.12%	-5.55%
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	443.50M	469.70M	456.10M	470.60M	491.50M	527.20M	548.00M	580.20M	670.70M	723.60M	706.50M	720.00M	771.30M	686.90M	716.60M	753.80M	747.40M	695.40M	702.10M	746.90M	-	698.00M	766.50M	804.60M	805.00M	844.90M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	466.10M	492.60M	510.30M	501.10M	548.50M
Gross Profit	121.80M	109.90M	109.70M	118.20M	108.30M	123.30M	133.30M	121.10M	134.20M	125.00M	125.10M	134.40M	142.20M	135.60M	146.80M	157.90M	147.80M	153.20M	167.00M	195.10M	194.60M	211.10M	271.90M	315.10M	288.20M	284.60M	321.50M	268.00M	271.30M	291.40M	288.30M	230.20M	230.00M	264.70M	-	231.90M	273.90M	294.30M	303.90M	296.40M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	103.80M	104.30M	115.00M	119.80M	-	115.30M
Operating Income	54.10M	44.00M	47.80M	39.10M	-3.50M	30.00M	61.20M	51.30M	60.50M	42.00M	62.90M	53.40M	60.30M	60.80M	70.70M	80.50M	67.30M	-	88.00M	103.60M	99.20M	-	175.60M	211.30M	181.40M	189.70M	228.40M	186.20M	155.30M	182.50M	177.30M	122.80M	126.20M	161.30M	-	127.60M	158.90M	174.50M	175.10M	181.10M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	150.90M	198.50M	215.10M	208.30M	227.20M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	400.00K	100.00K	200.00K	-200.00K	1.90M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	110.50M	157.00M	171.90M	161.50M	180.10M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24.10M	30.20M	34.00M	33.30M	44.70M
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55.40M	66.10M	56.30M	63.90M	74.30M	91.20M	82.30M	98.40M	151.20M	187.30M	175.60M	173.80M	188.50M	120.60M	140.00M	155.10M	161.30M	115.30M	111.30M	136.00M	-	89.80M	131.80M	140.00M	132.10M	138.80M
Diluted EPS	0.52	0.43	0.45	0.38	0.02	0.30	0.60	0.50	0.81	0.51	0.67	0.58	0.75	0.73	0.73	0.88	0.75	0.84	0.99	1.21	1.09	1.29	1.99	2.47	2.31	2.29	2.48	1.59	1.85	2.06	2.14	1.55	1.51	1.85	-	1.23	1.82	1.92	1.82	1.92
R&D Expense	9.90M	9.60M	7.50M	8.10M	8.50M	9.40M	8.80M	9.00M	10.30M	10.00M	9.10M	9.60M	10.80M	10.10M	9.80M	9.60M	9.30M	-	10.70M	10.80M	12.50M	-	12.20M	13.80M	13.10M	14.60M	14.40M	13.60M	17.10M	16.50M	16.40M	17.60M	17.50M	15.50M	-	16.30M	19.10M	17.10M	-	15.80M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	1.05B	1.06B	1.10B	1.19B	1.27B	1.37B	1.42B	1.40B	1.51B	1.60B	1.72B	1.84B	2.15B	-	2.89B	2.95B	2.89B	3.07B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.75B	1.82B	1.89B	1.97B
Gross Profit	302.60M	303.60M	318.10M	339.30M	387.70M	434.70M	447.80M	455.80M	501.40M	512.90M	545.40M	605.70M	767.80M	-	1.14B	1.13B	998.50M	1.10B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	375.40M	421.80M	407.60M	467.90M
Operating Income	124.10M	97.50M	90.70M	109.60M	135.10M	162.40M	182.00M	128.60M	195.20M	225.80M	240.30M	296.60M	406.90M	-	760.80M	707.40M	590.90M	636.10M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	808.40M	844.30M	743.90M	772.80M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.90M	9.00M	3.00M	500.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	679.90M	698.00M	585.50M	600.90M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	114.70M	122.30M	107.50M	121.60M
Net Income	86.00M	72.60M	65.30M	-	-	-	-	-	-	-	206.90M	241.70M	346.20M	-	585.90M	593.40M	492.70M	493.70M
Diluted EPS	2.50	2.12	1.89	1.08	1.15	1.57	1.75	1.30	1.91	1.99	2.74	3.21	4.57	-	7.73	7.88	6.69	6.79
R&D Expense	18.70M	19.90M	23.90M	29.10M	33.20M	37.90M	37.30M	34.10M	36.80M	39.10M	40.30M	38.90M	46.90M	52.80M	58.50M	68.40M	69.10M	74.30M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Sep 2011	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	1.27B	1.29B	-	1.40B	1.56B	1.67B	1.67B	1.70B	1.72B	1.86B	1.98B	2.34B	2.79B	-	3.62B	3.83B	3.64B	4.27B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.92B	1.94B	1.54B	1.98B
Cash & Equivalents	108.40M	87.20M	83.10M	110.20M	161.90M	91.80M	161.90M	230.00M	255.30M	274.60M	203.00M	235.90M	337.40M	439.10M	615.50M	-	894.30M	853.90M	484.60M	791.30M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	414.80M	434.70M	377.00M	443.90M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	507.40M	512.00M	552.50M	574.40M
Total Liabilities	-	-	691.90M	668.60M	-	744.20M	835.10M	765.20M	712.80M	671.20M	599.20M	582.90M	582.60M	768.20M	939.30M	-	931.90M	948.50M	961.10M	1.09B
Current Liabilities	-	-	171.10M	169.70M	-	243.20M	261.80M	236.90M	252.50M	314.30M	241.00M	279.50M	283.70M	341.60M	503.40M	-	519.00M	671.80M	550.40M	654.90M
Long Term Debt	-	-	379.10M	358.10M	-	299.30M	378.80M	371.30M	308.30M	228.90M	226.20M	197.00M	196.00M	255.00M	252.90M	-	206.70M	72.80M	202.60M	202.80M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	317.90M	309.00M	302.30M	321.10M
Total Equity	490.90M	487.10M	579.10M	625.70M	-	654.90M	728.90M	906.40M	956.90M	1.02B	1.12B	1.28B	1.40B	1.57B	1.85B	-	2.68B	2.88B	2.68B	3.18B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	75.30M	75.30M	75.30M	75.34M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	135.00M	137.70M	138.30M	130.70M	187.40M	220.50M	182.90M	212.40M	219.40M	263.30M	288.60M	367.20M	472.50M	-	724.00M	776.50M	653.40M	754.80M
Investing Cash Flow	-119.70M	-121.90M	-74.00M	-120.50M	-116.00M	-149.90M	-104.00M	-129.50M	-175.80M	-133.60M	-100.80M	-228.00M	-179.50M	-	-288.20M	-368.70M	-378.70M	-285.90M
Financing Cash Flow	-29.40M	-22.60M	-34.00M	-24.70M	-3.40M	-5.10M	-30.80M	-41.50M	-113.90M	-109.00M	-80.70M	-36.80M	-137.10M	-	-293.60M	-459.60M	-622.60M	-185.10M
Capital Expenditure	-138.60M	-104.90M	-71.10M	-95.40M	-131.30M	-151.90M	-111.90M	-131.60M	-170.20M	-130.80M	-104.70M	-126.40M	-174.40M	-	-284.60M	-362.00M	-377.00M	-285.90M
Free Cash Flow	-3.60M	32.80M	67.20M	35.30M	56.10M	68.60M	71.00M	80.80M	49.20M	132.50M	183.90M	240.80M	298.10M	-	439.40M	414.50M	276.40M	468.90M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	142.20M	-51.80M	-347.90M	283.80M
Share Buybacks	5.20M	1.30M	2.10M	3.50M	4.70M	-	0	0	52.20M	74.40M	70.80M	83.10M	115.50M	137.10M	202.80M	438.30M	560.90M	134.00M

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	28.8%	28.8%	28.8%	28.5%	30.6%	31.8%	31.5%	32.6%	33.2%	32.1%	31.8%	32.9%	35.8%	-	39.4%	38.3%	34.5%	35.9%
Operating Margin %	11.8%	9.2%	8.2%	9.2%	10.7%	11.9%	12.8%	9.2%	12.9%	14.1%	14.0%	16.1%	19.0%	-	26.4%	24.0%	20.4%	20.7%
Net Margin %	8.2%	6.9%	5.9%	-	-	-	-	-	-	-	12.0%	13.1%	16.1%	-	20.3%	20.1%	17.0%	16.1%
ROE %	17.7%	12.5%	10.4%	-	-	-	-	-	-	-	14.8%	15.4%	18.7%	-	21.8%	20.6%	18.4%	15.5%
ROCE %	-	8.9%	8.1%	9.5%	10.4%	11.3%	12.8%	9.3%	13.2%	14.3%	14.2%	14.8%	17.8%	-	24.6%	22.4%	19.1%	17.6%

Shareholding Pattern

Insiders

0.64%

Institutions

104.00%

Public Float

104.66%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.68%	6.84M	$2.46B
2	Vanguard Capital Management LLC	6.63%	4.68M	$1.69B
3	Vanguard Portfolio Management LLC	5.79%	4.09M	$1.48B
4	State Street Corporation	4.66%	3.29M	$1.19B
5	Artisan Partners Limited Partnership	3.76%	2.66M	$958.21M
6	Bank Of New York Mellon Corporation	3.49%	2.47M	$888.98M
7	T. Rowe Price Investment Management, Inc.	3.31%	2.34M	$843.75M
8	Generation Investment Management LLP	3.18%	2.24M	$808.99M
9	Geode Capital Management, LLC	2.71%	1.91M	$689.47M
10	Morgan Stanley	2.06%	1.46M	$525.73M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for WST

Google News Mon, 13 Jul 2026

3 Reasons WST is Risky and 1 Stock to Buy Instead - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxOanNGcWdvLWdLUUZhLXgwT202OUwxaFlnNDFXbkQzYWlsbEtwdnpfbkhJdTUxX3hsR2hFY2lveERUN2ZVWnBVXzhYZDhIbzVGSERQczZVdjE4WnRxckpkcmExVXFtd0YwOTNxU3hMdjI0bWlvRzFHYS1xelRlTVFYdWpWSzBxQS0xSERiUX…

Google News ue, 14 Jul 2026

West Pharmaceutical (NYSE: WST) inks 10-year Daikyo licensing, distribution deal - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNemhtWm5jbHVSSTBkakltajd5dlNzNnZGVXFrdkpFWkdWbWxxamgwRjVIV0taZ3VxTnJvZkRUTTJhR1lWd19UOU1wT0hISTVTRTA3Rk5SMXRFeEVCYS1wVDkwQmhhWlNBdTNzc1ZBbUtoWW5wbnRwYk9aUHVkci1rQzhfal9kdUxfeWVwT3…

Google News Wed, 08 Jul 2026

West Pharmaceutical Services (WST) Stock Looks Pricey On Strong Q2 Earnings Hopes - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxQeHl0b1MyaV9POElwTmhNSWxZU1U1TnV1NktaSkNSaktmT2JveUdvYTl2Vm8ta29pYXAzdTR5T1dpTXM0bnhqT0pzdGc1eU1xYUUzSzNWUjYwdHVIT2hhWUUyeDNQa3ZWdTgyTWhWUzJSTzR2djVpSm9CS3RyVEtyNGw1R1NFc1cwQm9McD…

Google News Mon, 13 Jul 2026

WST Initiated by BNP Paribas -- Rating Set to Outperform - GuruFocus

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQWEhVTndBTDJoeU84N0dPUDJvZHZ6OExxcFd3VnVMQU44RnBiOEZuRE9wUk5QUVdnRi1ud0xRLVZWUU9sTmdIdEZVbHFMSlR0ck1ySV9JeTR0MVBBUkltc21WekJaWl9tQWdkcnJ5OFM5MDIzWXkyMXduR2hSVTZaQkxwMWgtNWhOTE9LVz…

Google News Fri, 03 Jul 2026

West Pharmaceutical Services Stock 10-Day Winning Spree: Stock Climbs 13% - Trefis

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPQnNxcFMzczlQRmVnakhDeTgzTExIZjZrZmlGUnFjZV9SSWJ1ZWlsT3l0djFSLXg4VUdmdzNEREpWUUNwLWxKOGl5Ukx4Nnh5RC0zTFUycFBhNWtuY05zbXNMdFBjTkg3aEVsUl9xOUVXLXJPTXBXaUNXX0JiaGhoNmRBLXdYMFc1aTBmSk…

Google News Sun, 21 Jun 2026

West Pharmaceutical Services (WST) Stock Could Be 6.9% Undervalued on GLP 1 Growth Narrative - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPVzdmcmtlYmxuVm5YSlRvVW5pY0FjRGhieGtDQkNKbjFISjRmQmJiNHNsdjVzRFpnZS1PU3JqSUExeGlsV05YTE5rbnJPMlNUdUxpUTJKRkhIY0NyV3p2a0N1MlZ2MEc2MGl0bTR1SmtKTldhNzVQNUtabGc4cjlEUlBOSGI2eTBPbnNFbm…

WST — Frequently Asked Questions

What is the current share price of West Pharmaceutical Services, Inc. (WST)?

As of 2026-07-14 21:23 PDT, West Pharmaceutical Services, Inc. (WST) trades at $357.65 on NYSE. Its 52-week range is $209.39 to $365.74.

What is the market capitalisation of WST?

West Pharmaceutical Services, Inc. (WST) has a market capitalisation of $25.27B on NYSE.

What is the P/E ratio of WST?

WST trades at a trailing price-to-earnings (P/E) ratio of 47.69. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 8.55.

Does WST pay a dividend?

West Pharmaceutical Services, Inc. (WST) currently offers a dividend yield of 0.24%.

What is the return on equity (ROE) of WST?

WST has a return on equity (ROE) of 19.13%. Its return on capital employed (ROCE) is 16.28%.

Is WST a good stock to buy?

This page provides a data-driven analysis of West Pharmaceutical Services, Inc. (WST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

West Pharmaceutical Services, Inc. WST SPX

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

3 Reasons WST is Risky and 1 Stock to Buy Instead - Yahoo Finance

West Pharmaceutical (NYSE: WST) inks 10-year Daikyo licensing, distribution deal - Stock Titan

West Pharmaceutical Services (WST) Stock Looks Pricey On Strong Q2 Earnings Hopes - simplywall.st

WST Initiated by BNP Paribas -- Rating Set to Outperform - GuruFocus

West Pharmaceutical Services Stock 10-Day Winning Spree: Stock Climbs 13% - Trefis

West Pharmaceutical Services (WST) Stock Could Be 6.9% Undervalued on GLP 1 Growth Narrative - Yahoo Finance

WST — Frequently Asked Questions

What is the current share price of West Pharmaceutical Services, Inc. (WST)?

What is the market capitalisation of WST?

What is the P/E ratio of WST?

Does WST pay a dividend?

What is the return on equity (ROE) of WST?

Is WST a good stock to buy?

Explore More